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Abstract
The ERG gene belongs to the ETS family of transcription factors and has been found to be involved in atypical chromosomal
rearrangements in several cancers. To gain insight into the oncogenic activity of ERG, we compared the gene expression
profile of NIH-3T3 cells stably expressing the coding regions of the three main ERG oncogenic fusions: TMPRSS2/ERG (tERG),
EWS/ERG and FUS/ERG. We found that all three ERG fusions significantly up-regulate PIM1 expression in the NIH-3T3 cell
line. PIM1 is a serine/threonine kinase frequently over-expressed in cancers of haematological and epithelial origin. We show
here that tERG expression induces PIM1 in the non-malignant prostate cell line RWPE-1, strengthening the relation between
tERG and PIM1 up-regulation in the initial stages of prostate carcinogenesis. Silencing of tERG reversed PIM1 induction. A
significant association between ERG and PIM1 expression in clinical prostate carcinoma specimens was found, suggesting
that such a mechanism may be relevant in vivo. Chromatin Immunoprecipitation experiments showed that tERG directly
binds to PIM1 promoter in the RWPE-1 prostate cell line, suggesting that tERG could be a direct regulator of PIM1
expression. The up-regulation of PIM1 induced by tERG over-expression significantly modified Cyclin B1 levels and increased
the percentage of aneuploid cells in the RWPE-1 cell line after taxane-based treatment. Here we provide the first evidence
for an ERG-mediated PIM1 up-regulation in prostate cells in vitro and in vivo, suggesting a direct effect of ERG transcriptional
activity in the alteration of genetic stability.
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Introduction
Distinct alterations of the transcription factor ERG, an ETS-
related gene, are observed in a variety of cancers. Aberrant
expression of full-length ERG protein has been found in acute
myeloid leukaemia and acute T-lymphoblastic leukaemia [1,2].
Chromosomal rearrangements driving the formation of EWS/
ERG and FUS/ERG fusion proteins have been described in a
subset of Ewing sarcoma [3,4] and in acute myeloid leukaemia [5–
7]. A significant part of ERG sequence is lost in these fusions [4,7],
as the entire NH2-terminal pointed-domain is missing. The EWS
and FUS genes encode for two related RNA-binding proteins that
lose their RNA binding domains during translocation with ERG.
The resulting fusion proteins maintain the EWS or the FUS
transactivator domains (able to bind to RNA polymerase II) and
both acquire the ERG-derived DNA-binding domain [8–10]. In
2005 the most frequent genetic alteration involving ERG was
found in prostate cancer (PCa), where the 59-untrascribed region
of the prostate-specific and androgen-responsive TMPRSS2 gene
is fused to ERG in approximately 50% of PCa cases [11]. As a
consequence of this genetic alteration the TMPRSS2 promoter
region determines the inappropriate and androgen-driven expres-
sion of ERG in prostate cells. Several tERG alternative fusions
have been identified [12]. In the most common rearrangement
(T1/E4), a truncated ERG protein (tERG) that maintains its ERG
DNA-binding domain is expressed. Since the first three exons are
lost during rearrangement, an alternative translation initiation site
from an internal ATG codon is used to translate the fusion
transcript [13].
tERG, EWS/ERG and FUS/ERG fusions are all considered
early events in cancer progression. However, in contrast to the
established oncogenic properties of EWS/ERG and FUS/ERG
[14–16], tERG is clearly not sufficient to generate a fully
transformed phenotype in vitro and in vivo [17–20], although it
seems able to induce pre-neoplastic changes. Despite this, when
tERG is combined with additional genetic alterations that are
typical of PCa, such as aberrant PI3K signalling activation or
enhanced androgen receptor signalling, it can lead to an aggressive
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e28162disease [17,20]. All these lesions are not able to induce tumoral
transformation in prostate cells as single events, but the synergism
between them and the tERG rearrangement is sufficient to
promote PCa progression [17]. It is thus reasonable to hypothesize
that since tERG is an early event found at high frequency in PCa
specimens but lacks strong oncogenic features, it may promote the
progression towards a neoplastic phenotype by favouring the
achievement of secondary alterations. In line with this, it has
recently been shown that tERG over-expression can induce an
increase in the amount of double strand breaks in prostate cells,
thus creating a putative ‘‘error-prone’’ phenotype [21]. However,
this effect is not linked to a modified expression of DNA repair
genes, while it seems associated with the direct binding of tERG to
Poly(ADP-Ribose)Polymerase 1 (PARP-1) [21].
In this study we show that expression of the coding regions of
the three main ERG rearrangements (EWS/ERG, FUS/ERG
and tERG) up-regulate PIM1, an oncogene found increased in a
broad range of tumours of both epithelial and haematological
origin, including PCa [22–27] where its over-expression has been
associated with genomic instability [28–30]. To investigate the link
between tERG and PIM1 in prostate cancer, we modulated ERG
expression in the non malignant RWPE-1 prostate cell line. Our
results reveal that PIM1 is a direct target of tERG and that this
effect can favour genomic instability in a pre-cancerous environ-
ment.
Results
Overexpression of ERG oncogenic forms in NIH-3T3 cells
The coding regions of human tERG (T1/E4) [12], FUS/ERG
(isoform B) [9] and EWS/ERG (isoform 1e) [10] were inserted
into the phCMV2 vector. The derived phCMV2_HA_tERG,
phCMV2_HA_FUS/ERG and phCMV2_HA_EWS/ERG plas-
mids were introduced into the highly transfectable NIH-3T3
fibroblast cell line. In order to obtain reliable results, three
independent transfections were performed for each plasmid.
Western blot analysis of stable transfectants (Fig. 1A) showed the
presence of the ectopic proteins in all the populations. The over-
expression of ERG in all the tERG-positive populations was
confirmed also by quantitative Real-Time PCR (134596690.4
fold change compared to empty vector-transfected cells; data not
shown). Tritiated-thymidine incorporation assay revealed that
tERG over-expression is not sufficient to induce a significant
increase in the proliferative potential of NIH-3T3 cells compared
to control cells transfected with empty vector (hereafter referred to
as empty). Conversely, we observed a significant hyper-prolifer-
ative activity for the EWS/ERG and the FUS/ERG fusions
(p,0.05) (Fig. 1B).
Gene expression signature in NIH-3T3 cells transfectants
To dissect the effect of the three ERG fusions in a homogeneous
cellular model, we analyzed the gene expression signature for each
NIH-3T3 transfectant using a microarray-based gene expression
profiling approach covering more than 28,000 genes (see Materials
and Methods for detail). The results showed that, compared with
control cells, tERG, FUS/ERG and EWS/ERG induced a $1.5-
fold significant deregulation of 646, 798 and 1006 genes,
respectively. Some of the deregulated genes were randomly
chosen, and the expression was measured by quantitative Real-
Time-PCR. The results were compatible with microarray data
(Table 1). Venn diagrams reveal the presence of 183 common
deregulated genes (Fig. 1C). Among them we observed up-
Figure 1. Overexpression of HA-tagged TMPRSS2/ERG (tERG), EWS/ERG (E/E) and FUS/ERG (F/E) in NIH-3T3 cells. a) Anti-HA
immunoblot of NIH-3T3 whole cell lysates. Each transfection was performed in triplicate. Actin was used as a loading control. b) Evaluation of NIH-3T3
proliferative activity through [3H]Thymidine incorporation assay after 48 hrs of growth. Data for each ERG form represent the average of the results of
the three independent populations and are normalized against the average of NIH-3T3_empty vector cells (*p,0.05). c) Venn diagrams of the
transcription profiles of NIH-3T3 transfectants considering genes with a cut-off $1.5 fold differential expression compared to control cells (NIH3T3-
empty). d) Graphic representation of the top 10 highly significant molecular and cellular function categories identified by the common 183
deregulated genes. Categories ranking was obtained by Ingenuity Pathway Software. Significance refers to the 2log(p-value), which was obtained by
the Ingenuity program using a right-tailed Fisher’s exact test.
doi:10.1371/journal.pone.0028162.g001
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target genes [18,31], thus confirming the reliability of our model
(Table 1). We used the Ingenuity Pathway Analysis (IPA) to
annotate the functional categories of the significantly deregulated
genes. In Figure 1D the first 10 top-ranking molecular and cellular
function categories identified by the 183 commonly deregulated
genes are shown.
Co-expression of ERG and PIM1 in prostate cancer
Among the genes significantly affected by all three ERG
fusions (Fig. 1C), we noted the up-regulation of PIM1, an
oncogene whose expression is increased in tumors from both
haematological and epithelial origin, including prostate cancer
[22,32,33]. These data were further confirmed by quantitative
RT-PCR on NIH-3T3 transfectants for all the ERG oncogenic
forms (Fig. 2A). In addition, examination of prostate cell lines
showed a highly significant difference in PIM1 expression
between the tERG positive and negative cell lines (p,0.001)
(Fig. 2B). We then found a significant (p,0.01) correlation
between ERG expression and PIM1 up-regulation in a prostate
cancer dataset [34], further confirming the link between ERG
and PIM1 in prostate cancer (Fig. 2C). The presence of the tERG
fusion in three distinct prostate cancer samples and in a matched
non-tumoral adjacent tissue from patient #3 was then evaluated
(Fig. 2D). Samples #2a n d#3 proved to be tERG positive, with
the corresponding non-tumoral sample (#3NT) being negative.
Sample #2a n d#3 (tERG positive) showed significantly higher
PIM1 expression than sample #1 (Fig. 2E). In addition, tumour
tissue from patient #3 displayed higher PIM1 and ERG levels
than the corresponding autologous non-malignant prostate
(Fig. 2F).
Table 1. Validation of gene expression deregulation through
quantitative Real-Time PCR in NIH-3T3 transfectants.
GENE (official
gene symbol) empty tERG EWS/ERG FUS/ERG
Cdh5 1 (q) +33.7 (q) +8.1 (q) +12.4
Mmp3 1 (q) +63.8 (q) +79.86 (q) +243.9
Edn1 1 (q) +31.9 (q) +14.7 (q) +21.5
Irs1 1 (n) +1.2 (q) +2.07 (q) +2.49
Egln3 1 (q) +4.6 (q) +4.3 (q) +2.3
Dpysl3 1 (q) +5.2 (q) +7.2 (q) +7
Cyp1b1 1 (n) +1.1 (q) +9.7 (q) +5
Has2 1 (Q) 21.9 (Q) 26.9 (Q) 27.3
Ednra 1 (q) +4.8 (q) +11.4 (q) +42
Ccl9 1 (q) +9( q) +3.1 (q) +2.1
Gpr149 1 (q) +5.7 (q) +7( q) +5.7
Id1 1 (Q) 29.2 (n) 21.9 (n) 21.3
Significant up- (q) or down- (Q) regulation obtained by microarray analysis is
shown alongside quantitative Real-Time PCR fold change values for a direct
comparison. n=no change.
doi:10.1371/journal.pone.0028162.t001
Figure 2. Significant co-expression of ERG and PIM1. a) PIM1 expression fold change in NIH-3T3 transfectants compared to empty-vector cells,
as determined by Quantitative Real-Time PCR (***=p,0.001). b) Quantitative Real-Time PCR for PIM1 in human prostate cell lines. PIM1 expression,
relative to the non-malignant RWPE-1 cell line is visualized in the graph (***=p,0.001). tERG positivity is shown. c) Correlation between ERG and
PIM1 expression in prostate samples from the Kunderfranco et al dataset [34]. The Spearman rank correlation test was used to estimate the
correlation significance (p=0.0016; r=0.3779). d) cDNA prepared from human prostate samples (tumors #1 and #2, plus a matched tumoral/non-
tumoral pair [#3T/#3NT]) and from the tERG-positive VCaP cell line, was amplified as described in materials and methods. The arrows indicate the
tERG amplified products. d–e) Quantitative Real-Time PCR for ERG and PIM1 in prostate cancer samples. Relative ERG and PIM1 expression compared
to the tERG-negative prostate cancer #1( d) or to the non-tumoral sample #3NT (e) is reported. **=p,0.01; ***=p,0.001; T=tumoral; NT=non-
tumoral.
doi:10.1371/journal.pone.0028162.g002
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modulates PIM1 expression
To gain further insights into the role of tERG-mediated PIM1
induction in prostate cancer progression, we stably over-expressed
tERG in the non-tumorigenic prostate epithelial cell line RWPE-1.
tERG over-expression induced PIM1 both at the mRNA (3.160.5
fold change compared to empty cells) and protein levels (Fig. 3A–
B). Furthermore, ERG silencing in RWPE-1_tERG transfectants
led to PIM1 down-regulation, confirming the role of the ERG
transcription factor in PIM1 induction (Fig. 3C). To address the
interaction between tERG and PIM1 promoter, anti-HA chro-
matin immunoprecipitates (ChIP) from RWPE-1_tERG cells were
subjected to quantitative RT-PCR using primers specific for the
region from 22095 bp to 22289 bp upstream of the ATG start
codon of PIM1 (NC_000006) (Fig. 3D). This 194 bp stretch
includes a putative ERG binding site (GGAAGTG) as defined by
the Transcription Element Search System (TESS-http://www.
cbil.upenn.edu/cgi-bin/tess). ChIP analysis showed a significant
enrichment of PIM1 promoter compared to a region in the
GAPDH promoter where no ERG binding sites are present
(Fig. 3E–F).
RWPE-1 cells over-expressing the tERG/PIM1 axis display
a slower rate of recovery after treatment with
chemotherapeutic drugs
tERG over-expression did not confer a growth advantage to
RWPE-1 cells in standard conditions (Fig. 4A). PIM1 is an
oncogene whose over-expression has been associated to the
acquisition of drug resistance in prostate cancer [35–37]. As
evaluated by IC50 values (Fig. 4B–C), RWPE-1_tERG transfec-
tants did not display increased resistance to taxane, nor to
anthracycline-based drugs (IC50 empty vs tERG: Idarubicin-HCl
1.57 uM vs 0.79 uM; Taxol 5.05 nM vs 2.71 nM). However the
quantification of re-growth of transiently treated cultures showed
an early protection in taxane-treated cells, followed by a later
decrease in the proliferative rate for tERG positive cells compared
Figure 3. ERG dependent PIM1 induction in RWPE-1 cells. a–b) PIM1 over-expression in RWPE-1 transfected with HA-tagged TMPRSS2/ERG
coding region (RWPE-1_tERG) as evidenced by immunoblot (a) and Real-Time quantitative PCR (b). Actin is shown as a loading control. ERG and PIM1
fold changes were normalized against empty-vector cells. c) siRNA knockdown of ERG (siERG) in RWPE-1_tERG induces a decrease in PIM1 levels
compared to non-targeting siRNA (siNT). d) Sequence of the 194 bp-long PIM1 promoter region amplified in ChIP analysis. The 7 bp putative ERG
binding site identified by Transcription Element Search System (TESS) is shown in italic. The distances from the ATG starting site are presented. e–f)
Chromatin Immunoprecipitation (ChIP) showed a significant enrichment of HA-tERG binding to PIM1 promoter compared to IgG control in RWPE-
1_tERG. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) promoter was used as a negative control. **=p,0.01.
doi:10.1371/journal.pone.0028162.g003
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linked to a lower ability to recover from DNA-damaging drugs,
and in particular from drugs blocking the G2/M switch, in the non
malignant RWPE-1 cell line.
ERG-dependent PIM1 induction deregulates cyclin B1
level and favours the appearance of aneuploidy
The slower recovery of RWPE-1_tERG cells after treatment
with chemotherapeutic drugs, prompted us to investigate
whether the tERG/PIM1 axis could affect genetic stability in
early phases of prostate cancer progression. It has been
previously described that PIM1 over-expression can induce
aneuploidy in RWPE-1 cells and increases cyclin B1 levels thus
deregulating the G2/M phase of the cell cycle [29]. We first
assessed cyclin B1 protein amount in RWPE-1 transfectants. We
found that tERG-positive cells display higher cyclin B1 levels
compared to empty cells, and that PIM1 silencing reduces its
over-expression (Fig. 5A). Flow-cytometry (FACS) analysis of
propidium iodide-stained RWPE-1 cells did not show differences
in cell cycle profile between empty and tERG transfectants
(Fig. 5B). However, we observed a significant increase in the
amount of .4n cells after taxol-induced microtubule stress in
tERG-positive compared to empty cells (Fig. 5B–C). Taxol
treatment of RWPE-1 transfectants revealed an increased
viability of tERG cells compared to empty cells after 42 hours
of treatment (Fig. 5D). Furthermore, PIM1 silencing in RWPE-
1_tERG cells caused a moderate decrease in the aneuploid
portion of RWPE-1_tERG taxol-treated cells (from 7.0363.2%
in the non targeting silencing to 4.8460.64% in the PIM1
specific silencing after 24 hours treatment; data not shown)
T h e s ed a t as u g g e s tad i r e c te f f e c to ft h et E R G / P I M 1a x i si nt h e
alteration of genomic stability in pre-malignant prostate cells.
Discussion
The ETS family of transcription factors, comprising more than
20 genes, has been associated to the pathogenesis of several cancers,
often due to gene rearrangements involving the ETS domain. ERG
is one of the most affected members of the family, being involved in
several chromosomal translocations in different tumors. Here we
used a homogeneous cellular model to compare the effect of the
three main ERG oncogenic forms found in tumoral specimens and
derived from non canonical chromosomal rearrangements: tERG,
EWS/ERG and FUS/ERG. Gene expression analysis of NIH-3T3
transfectants revealed a minimum overlap in the affected genes
despitethemaintenanceoftheERGDNAbindingdomaininallthe
three fusions. The 183 commonly deregulated genes represented
28.3%, 22.9% and 18.1% of the entire differentially expressed gene
set for tERG, FUS/ERG and EWS/ERG, respectively.
This study shows for the first time that tERG, EWS/ERG and
FUS/ERG can significantly up-regulate the transcription of the
serine/threonine kinase PIM1 in the NIH-3T3 cell line. PIM1 was
of immediate interest because it is supposed to play an oncogenic
role in several types of tumours, including prostate cancer
[22,32,33]. Since we found a significant correlation between
ERG-expression and PIM1 upregulation in a previous published
prostate cancer data-set [34], we evaluated several prostate cancer
specimens and prostate cancer cell lines for ERG and PIM1
expression, confirming a significant correlation between ERG and
PIM1 mRNA levels. Quantitative Real-Time PCR analysis of an
ERG-positive tumour and the corresponding non-tumoral adja-
cent tissue validated the connection between ERG and PIM1 at
the transcriptional level. The association between ERG and PIM1
expression in clinical specimens suggests that such a mechanism
may be relevant in ERG induced prostate tumorigenesis in vivo.
Figure 4. Sensitivity of RWPE-1_tERG cells to chemotherapeutic drugs. a) Proliferative potential of tERG over-expressing and control
(empty) cells measured by thymidine uptake assay up to 72 hrs growth in standard conditions. b–c) 72 hours treatment of RWPE-1 transfectants with
taxol or idarubicin-hydrochloride. Proliferative potential was measured by thymidine uptake assay. d–e) Re-growth of RWPE-1 transfectants after
10 nM taxol (d) or 0.5 mM idarubcicin-hydrochloride (e): following 24-hrs treatment, drugs were removed and the cells allowed to grow for additional
72 hours. Proliferation of cells collected at the time of wash-out is set as 100%. *=p,0.05.
doi:10.1371/journal.pone.0028162.g004
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[38,39], we modulated tERG expression in the non-tumorigenic
immortalized RWPE-1 prostate cell line. We showed here that
PIM1 levels changed in accordance to tERG amount also in a
non-malignant prostate model and that tERG can directly bind to
PIM1 promoter. Since it has previously been observed that PIM1
over-expression can exert a pro-survival activity in prostate cancer
cells treated with chemoterapeutic drugs [40,41], we tried to assess
whether this phenomenon can be observed also in the non-
tumoral RWPE-1 model. Our results showed that the tERG/
PIM1 axis is unable to induce sustained resistance to taxane or
anthracycline-based drugs in pre-malignant lesions, but signifi-
cantly increases the sensitivity of non-tumoral cells in a re-growth
assay after drug treatments. Since sensitivity to chemotherapeutic
drugs can be a consequence of increased genetic instability in cells,
we tried to understand whether the tERG mediated PIM1
induction could cause some form of genomic instability. PIM1 is
known to be important for the maintenance of a stable mitotic
apparatus and for the proper dynamics of spindles [28,42]. We
therefore looked at the development of aneuploidy following
treatment with a cytotoxic drug. Cell cycle analysis of our RWPE-
1 transfectants did not show significant differences between tERG
and empty cells. Despite this, treatment with paclitaxel, a taxane-
based microtubule-interacting drug, induces a significant increase
in the .4n population in the tERG positive cells, suggesting an
involvement of the tERG/PIM1 axis in the alteration of genomic
stability after cellular stresses. The central role of PIM1 in this
phenomenon was then confirmed through PIM1 transient
silencing in the paclitaxel-treated tERG cells. In addition we
demonstrated that tERG up-regulation can influence Cyclin B1
levels, an event previously associated with the appearance of
aneuploidy in PIM1 over-expressing prostate cells [29]. We here
showed that cyclin B1 increase in RWPE-1 transfectants is mostly
driven by PIM1 up-regulation, although it is not possible to
exclude additional regulatory mechanisms mediated by tERG
over-expression. In fact, transient PIM1 silencing was able to
modulate Cyclin B1 levels only in part.
It is widely accepted that the appearance of aneuploidy in non-
malignant cells can provide a favourable environment for the
acquisition of additional mutations. The stress caused by
aneuploidy can promote genomic changes and induces genetic
instability thus playing a causative role in early tumourigenesis
Figure 5. The tERG/PIM1 axis favours aneuploidy. a) Immunoblot assay demonstrates Cyclin B1 increase in RWPE-1_tERG cells. siRNA
knockdown of PIM1 (siPIM1) reduces this effect compared to non-targeting siRNA (siNT). The same amount of whole cell lysates were loaded in two
different polyacrilamide gels. The tERG_siPIM1 sample for the HA immunoblot was loaded in a different position compared to the gel for PIM1, Actin
and Cyclin B1 blot b) Flow cytometric analysis of non-synchronized propidium iodide stained cells. Treatment with taxol for 15/24/42 hours induces
an important increase in the .4n fraction of RWPE-1_tERG compared to empty cells. c) Percentage of .4n cells after taxol treatment obtained from
the average of at least two independent experiments. **=p,0.01, ***=p,0.001. d) Annexin-V assay was carried out to evaluate apoptosis after
42 hrs of 10 nM taxol treatment for RWPE-1 transfectants. The percentage of cells in each quadrant is shown.
doi:10.1371/journal.pone.0028162.g005
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sensitive to the acquisition of aneuploidy after taxane-based
treatment thanks to PIM1 induction. Furthermore, annexin-V
assay showed that at early time-points after taxol treatment tERG
cells display a lower level of apoptosis compared to control cells.
Therefore, the aptitude of RWPE-1_tERG cells to develop
aneuploidy and to avoid apoptosis at least in the initial phases
after a drug-induced stress, suggests the existence of a cellular
environment that favours genetic instability induced by the tERG/
PIM1 axis. We propose that TMPRSS2/ERG fusion, although
unable to confer growth advantage, renders epithelial cells prone
to the acquisition of new mutations, which will then be selected
during malignant transformation.
PIM1 expression is known to be elevated in approximately 50%
of prostate cancer cases [22]. Despite many efforts in the
identification of PIM1 kinase inhibitors for the treatment of
PCa, little is known about the regulation of PIM1 levels in
epithelial malignant cells. Here we provide the first evidence of an
ERG mediated PIM1 up-regulation in a non-tumoral prostate cell
line. We also suggest that a similar ERG-mediated regulation of
PIM1 expression could be present for the EWS/ERG and FUS/
ERG fusions. This discovery provides novel insights into the role
of TMPRSS2/ERG in prostate cancer progression and describes a
new mechanism for PIM1 regulation mediated by the ERG DNA
binding domain.
Materials and Methods
Prostate tumor specimens
Three localized prostate cancer samples and a non-neoplastic
paired tissue were taken freshly from total prostatectomy
specimens. This study was approved by the internal Ethical
Committee of San Gerardo Hospital. Pathology-certified, fully
anonimized human samples were provided according to local IRB
provision (San Gerardo Hospital IRB document ASG-DA-950,
april 2008). Patients provided written informed consent to donate
the tissues left over after diagnostic procedures.
Cell lines
The prostate cell lines RWPE-1, VCaP, LNCaP and 22Rv1
were obtained from the American Type Culture Collection
(ATCC), while the benign prostate hyperplasia (BPH-1) and the
NIH-3T3 mouse fibroblast cell lines were purchased from DSMZ.
The immortalized non malignant prostate cell line RWPE-1 was
maintained in keratinocyte-serum free medium supplemented with
epidermal growth factor and bovine pituitary extract. BPH-1 cells
were grown in RPMI supplemented with 20% fetal bovine serum,
20 ng/ml testosterone, 5 mg/ml transferrin, 5 ng/ml sodium
selenite and 5 mg/ml insulin. LNCaP and 22Rv1 cells were
maintained in RPMI while VCaP and NIH3T3 cell lines were
maintained in DMEM. In these latter cases both RPMI and
DMEM medium were supplemented with 10% FBS.
Generation of plasmids and transfections
The cDNA of the putative translated sequence of TMPRSS2/
ERG (isoform 9) [12] was obtained from the RNA of the prostate
cancer cell line VCaP and inserted into the phCMV2 vector
(Genlantis, CA, USA) through XhoI/NotI restriction sites to
obtain the phCMV2_HA_tERG plasmid. The FUS/ERG
(isoform B) [9] and EWS/ERG (isoform 1e) [10] cDNA sequences
were derived from pSG5-fl-FUS/ERG and pSG5-fl-EWS/ERG
respectively, kindly provided by Prof. Liu Yang [44,45] and
inserted into phCMV2 as above, to obtain phCMV2_HA_FUS/
ERG and phCMV2_HA_EWS/ERG. The primers used to
amplify the selected fragments for the cloning into phCMV2-HA
vector were: FUS/ERG_Fw 59tactcgagatggcctcaaacgattatacc39,
EWS/ERG_Fw 59tactcgagatggcgtccacggattacag39 and tERG_Fw
59tactcgagatgaccgcgtcctcctccagc39. The reverse primer for all the
ERG forms was ERG_Rw 59tatgcggccgcttagtagtaagtgcccagatg39.
The RWPE-1 cell line was transfected with Fugene 6 (Roche,
Applied Science, Germany) according to manufacturer’s instruc-
tion and selected for geneticin (Invitrogen, Carlsbad, CA, USA)
resistance at 0.25 mg/ml.
Retrotranscription and Quantitative Real-Time PCR
RNA was extracted with TRIzol Reagent (Invitrogen, Carlsbad,
CA, USA) and cDNA was synthesized from 200 ng of total RNA,
using ‘TaqMan Reverse Transcription Reagents’ (Applied Biosys-
tems, Foster City, CA, USA). The RNA from transfectant cells was
pre-treated with DnaseI (Invitrogen, Carlsbad, CA, USA) to avoid
contamination from genomic DNA. The TMPRSS2/ERG positiv-
ity was assayed on cDNA using the Fast Start Taq DNA polymerase
(Roche, Applied Science, Germany) with the primers TMPRSS2-
RT-fandTMPRSS2:ERG_RT-rasdescribedinTomlinsetal.[11].
Quantitative RT-PCR was performed using Brilliant SYBR Green
QPCR Master Mix (Stratagene, La Jolla, CA) on a Stratagene-
MX3005P under standard conditions. All the quantitative Real-
Time PCR experiments were performed in triplicate. Immediately
after amplification, PCR products were analyzed by sequencing,
dissociation curve analysis, and gel electrophoresis to determine
specificity of the reaction. The house-keeping genes GAPDH (homo
sapiens) and Gus (mus musculus) were used as endogenous
references. The sequences of the primers used are reported (hs:
homo sapiens, mm: mus musculus): GAPDHFw(hs) 59tgcaccac-
caactgcttagc39 and GAPDHRw(hs) 59ggcatggactgtggtcatgag39 [46];
ERGFw(hs) 59cgcagagttatcgtgccagcagat39 and ERGRw(hs) 59cca-
tattctttcaccgcccactcc39 [11]; PIM1Fw(hs) 59cgagcatgacgaagagatcat 39
and PIM1Rw(hs) 59tcgaaggttggcctatctga39 [47]; Hprt1Fw(mm) 59tca-
gtcaacgggggacataaa39 and Hprt1Rw(mm) 59ggggctgtactgcttaaccag39
[48]; Cdh5Fw(mm) 59agacacccccaacatgctac39 and Cdh5Rw(mm)
59gcaaactctccttggagcac39 [49]; Mmp3Fw(mm) 59aagggtggatgctgtcttt-
gaagc39 and Mmp3Rw(mm) 59gccatagcacatgctgaacaaagc39 [50];
Edn1Fw(mm) 59gcgtcgtaccgtatggactgg39 and Edn1Rw(mm) 59atgcctt-
gatgctattgctgatg39; Irs1Fw(mm) 59taggcagcaatgagggcaactc39 and
Irs1Rw(mm) 59tgaggtcctggttgtgaattg39; Egln3Fw(mm) 59ggcacctgc-
gaggcgaccagat39 and Egln3Rw(mm) 59tggcgaacataacctgtcccattt39;
Dpysl3Fw(mm) 59cgagcagcagcagtagcagcga39 and Dpysl3Rw(mm) 59a-
tgcctccagggatcaccatcttc39;C y p 1 b F w ( m m )59gcctgccactattacggaca39
and Cyp1b1Rw(mm) 59acaacctggtccaactcagc39 [51]; Has2Fw(mm)
59cgagtctatgagcaggagctg39 and Has2Rw(mm) 59gtgattccgaggaggaga-
gaca39 [52]; EdnraFw(mm) 59tacaagggcgagctgcatag39 and Edn-
raRw(mm) 59catgagggtgtagaagattgctg39;C c l 9 F w ( m m )59ggccagctgggt-
ctgcccac39 and Ccl9Rw(mm) 59tgcccggcctggtacacccac39; Gpr149F-
w(mm) 59cgttgccttcgatgggaaaaa39 and Gpr149Rw(mm) 59gctcctttgtag-
cttcacactca39;Id1Fw(mm) 59ttggtctgtcggagcaaagcgt39 and Id1Rw(mm)
59cgtgagtagcagccgttcatgt39; PIM1Fw(mm) 59gatcatcaagggccaagtgt39
and PIM1Rw(mm) 59gatggttccggatttcttca39 [53].
Chromatin Immunoprecipitation
Chromatin immunoprecipitation was performed as described
previously [54]. The DNA was immunoprecipitated with anti-HA
antibody (Abcam, Cambridge, UK) and subsequently amplified
with quantitative RT-PCR using SYBR Green QPCR Master Mix
(Stratagene, La Jolla, CA) on a Stratagene-MX3005P under
standard conditions. Results were quantified by SYBR Green
Real-Time PCR analysis (each sample was performed in
triplicate). The fold enrichment of immunoprecipitated samples
was normalized on INPUT and expressed relative to the mock-
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products by agarose gel with etidium bromide staining. The
primers used for the reactions were: ERG-ChIP-For
59GTGCTAGGCGAGTGGGAACAACTG39 and ERG-ChIP-
Rev 59AATGACCCAAATTCACCTCCTGAG39; GAPDH_-
ChIP_For 59CCCAACTTTCCCGCCTCTC39 and GAPDH_-
ChIP_Rev 59CAGCCGCCTGGTTCAACTG39.
Western Blot analysis
Western Blot was performed as previously described [55] using
the following antibodies: mouse anti-PIM1 (12H8) (Santa Cruz
Biothecnology, CA, USA), mouse anti-cyclin B1 (H-433) (Santa
Cruz Biotechnology, CA, USA), mouse anti-HA (Covance,
Princeton, NJ, USA), rabbit anti-Actin (Sigma-Aldrich, St Louis,
MO, USA).
RNA interference
Short interfering RNA knockdown of PIM1 and ERG were
performed with siRNA from the Thermo Scientific Dharmacon:
siGENOME_SMART_ pool (003923-00) and siGENOME_-
siRNA (D-003886-01) for PIM1 and tERG, respectively. siGEN-
OME_non targeting_siRNA (NT) was used as control (D-001210-
01-05). siRNA were transfected in RWPE1 cells as indicated using
Lipofectamine2000 (Invitrogen, Carlsbard, CA, USA). In PIM1
knockdown, cells were harvested after 72 hours from transfection
for RNA isolation or whole cell lysates. For siERG experiments,
transfections were performed as described in Tomlins et al. [18].
Gene expression profile
RNA from each population of stable transfectants was extracted
with TrizolHreagent (Invitrogen, Carlsbad, CA, USA) according to
guidelines. Expression profiling was performed with Affymetrix-
GenechipH Mouse Gene 1.0 ST Array according to manufactur-
er’s protocol. BRB-Array tools was used to highlight differentially
expressed genes. The array corresponding to one of the three
tERG pools did not pass the quality control, and therefore was not
included in subsequent statistical analysis. Note that ERG itself did
not appear as an up-regulated gene in any dataset, as the
ectopically expressed human ERG sequence does not hybridize to
mouse ERG probe used in the array. Raw data have been
deposited according to MIAME guidelines at NCBI Gene
Expression Omnibus (GSE32481).
Cell cycle and apoptosis analysis
For cell cycle analysis, cells were fixed in ethanol and stained
with propidium-iodide (Sigma-Aldrich, St Louis, MO, USA). To
evaluate apoptosis, Annexin-V assay was carried out with the
Annexin V-FITC apoptosis detection kit (Bender MedSystems,
Vienna, Austria) following the manufacturer’s instructions. Flow-
cytometry was performed on a Becton Dickinson FACSort by
CELLQuest software (Becton Dickinson Immunocytometry Sys-
tems, Mountain view, CA, USA).
Chemical compounds
Taxol and Idarubicin hydrochloride were obtained from Sigma-
Aldrich and were dissolved at the desired concentration following
guidelines.
Thymidine uptake assay
Exponentially growing NIH-3T3 or RWPE-1 transfectants were
plated in at least 4 replicates in 96 well plates at a density of 3000
cell/well. Where indicated, cells were treated with drugs or vehicle
alone. 1 mCi of [
3H]thymidine (Amersham) was added to each well
8 hours before harvesting onto glass fiber filters by a Tomtec
automated cell harvester. Incorporation of [
3H]thymidine was
measured using a filter scintillation counter (1430 MicroBeta).
Statistical analysis
GraphPad-Prism program was used to analyze the data. Two-
tailed unpaired t test was used to determine statistical significance
of the differences between data sets, where appropriate.
Spearman Rank correlation test was performed to analyze the
correlation between ERG and PIM1 expression in the available
prostate sample data-set (GSE14206) [34].
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